These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26516102)

  • 21. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
    Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
    Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gradual vs. wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis.
    Takeuchi H; Thiyanavadivel S; Agid O; Remington G
    Schizophr Res; 2017 Nov; 189():4-8. PubMed ID: 28242107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin add-on therapy in the antipsychotic treatment of schizophrenia: A meta-analysis.
    Nomura I; Kishi T; Ikuta T; Iwata N
    Psychiatry Res; 2018 Feb; 260():41-47. PubMed ID: 29172097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection of atypical antipsychotics for the management of schizophrenia.
    Sprague DA; Loewen PS; Raymond CB
    Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
    Nelson JC; Papakostas GI
    Am J Psychiatry; 2009 Sep; 166(9):980-91. PubMed ID: 19687129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.
    Correll CU; Maayan L; Kane J; Hert MD; Cohen D
    J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials.
    Galling B; Roldán A; Rietschel L; Hagi K; Walyzada F; Zheng W; Cao XL; Xiang YT; Kane JM; Correll CU
    Expert Opin Drug Saf; 2016 May; 15(5):591-612. PubMed ID: 26967126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.
    McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.
    Citrome L
    Expert Opin Pharmacother; 2012 Aug; 13(11):1545-73. PubMed ID: 21999805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis.
    Takeuchi H; MacKenzie NE; Samaroo D; Agid O; Remington G; Leucht S
    Schizophr Bull; 2020 Dec; 46(6):1439-1458. PubMed ID: 32415847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysis.
    Takeuchi H; Remington G
    J Psychopharmacol; 2020 Aug; 34(8):914-919. PubMed ID: 32448023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse effects of antipsychotics as outcome measures.
    Hamer S; Haddad PM
    Br J Psychiatry Suppl; 2007 Aug; 50():s64-70. PubMed ID: 18019047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis: Discontinuation in antipsychotic trials.
    Kishi T; Matsuda Y; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2020 Nov; 130():240-246. PubMed ID: 32846328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic discontinuation in patients with dementia: a systematic review and meta-analysis of published randomized controlled studies.
    Pan YJ; Wu CS; Gau SS; Chan HY; Banerjee S
    Dement Geriatr Cogn Disord; 2014; 37(3-4):125-40. PubMed ID: 24157687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between antipsychotics and cardiovascular adverse events: A systematic review.
    Silva AASD; Ribeiro MVMR; Sousa-Rodrigues CF; Barbosa FT
    Rev Assoc Med Bras (1992); 2017 Mar; 63(3):261-267. PubMed ID: 28489133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons.
    Tonin FS; Rotta I; Mendes AM; Pontarolo R
    Pharm Pract (Granada); 2017; 15(1):943. PubMed ID: 28503228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the Risk of Treatment Failure After Discontinuation of Long-Term Antipsychotic Treatment.
    Czobor P; Volavka J
    Am J Psychiatry; 2018 Sep; 175(9):908-909. PubMed ID: 30173547
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.